Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

Share Price is delayed by 15 minutes
Get Live Data
413.40    1.00 (0.24%)
Bid:
413.20
Ask:
413.60
Spread: 0.40 (0.097%)
Market Cap: £2.12b
QQ. Live PriceLast checked at - London Stock Exchange

Intraday Qinetiq Share Chart

Directorate Change

18 Mar 2024 07:00

RNS Number : 1439H
QinetiQ Group plc
18 March 2024
 

QinetiQ Group plc

 

Non-Executive Directorate Changes

 

18 March 2024 - QinetiQ Group plc ("QinetiQ") today announces that Lawrence (Larry) Prior III, who has been a Non-executive Director since August 2021, has resigned from the Board with effect from 16 March 2024.

 

Commenting on today's announcement, Larry Prior said:

 

"I have great respect and admiration for QinetiQ, its Board and its executive team, and it has been an honour and pleasure to serve. I find that I need to devote more time and attention to another role and challenge.

 

Neil Johnson, Group Chair of QinetiQ, further commented:

 

"I would like to thank Larry for his invaluable contribution to the QinetiQ Board over the past 3 years. I completely understand Larry's decision to stand down from the Board in order to focus his time on another corporate role. Nevertheless, his thoughtful advice will be missed. We all wish him well for the future."

 

9.6.11R of the Listing Rules of the UK Listing Authority:

 

This notice is given in fulfilment of the obligation under paragraph 9.6.11R of the Listing Rules. There are no other matters requiring disclosure under paragraph 9.6.11R.

 

S430(2B) Companies Act 2006:

 

Larry Prior has not and will not receive any loss of office payments, nor will he be paid any further remuneration for his service as a Director of QinetiQ, other than fees due for his services up to the date of his retirement from the Board.

 

About QinetiQ:

 

QinetiQ is an integrated global defence and security company focused on mission-led innovation. QinetiQ employs circa 8,500 highly-skilled people, committed to creating new ways of protecting what matters most; testing technologies, systems, and processes to make sure they meet operational needs; and enabling customers to deploy new and enhanced capabilities with the assurance they will deliver the performance required.

 

For further information, please contact:

 

John Haworth, Group Director Investor Relations: +44 (0) 7920 545841

Lindsay Walls, Group Director Communications: +44 (0) 7793 427582

James Field, Company Secretary: +44 (0) 7841 662957

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKDLFFZXLZBBB
Date   Source Headline
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM
20th Jul 20237:00 amRNSFirst Quarter Trading Update
11th Jul 20235:30 pmRNSDirector/PDMR Shareholding
21st Jun 202312:15 pmRNSDirector/PDMR Shareholding
14th Jun 202310:00 amRNSHolding(s) in Company
12th Jun 20234:00 pmRNSDirector/PDMR Shareholding
12th Jun 20232:00 pmRNSAnnual Financial Report
25th May 20237:00 amRNSResults for the year ended 31 March 2023
10th May 20234:55 pmRNSDirector/PDMR Shareholding
17th Apr 20237:00 amRNSFourth Quarter Trading Update
12th Apr 202311:35 amRNSDirector/PDMR Shareholding
5th Apr 20237:00 amRNSQinetiQ announces £259 million renewal of MSCA
30th Mar 20237:00 amRNSQinetiQ Awarded $92.6M Contract
23rd Mar 20235:00 pmRNSDirectorate Change
20th Mar 202310:30 amRNSDirector Declaration
15th Mar 20232:40 pmRNSDirector Declaration
10th Mar 20232:56 pmRNSDirector/PDMR Shareholding
17th Feb 20239:00 amRNSHolding(s) in Company
16th Feb 20237:00 amRNSGary Stewart appointed CEO for Australia Sector
10th Feb 20231:14 pmRNSDirector/PDMR Shareholding
6th Feb 20231:44 pmRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSThird Quarter Trading Update
16th Jan 20237:00 amRNS£80m contract win with UK MOD
10th Jan 20233:43 pmRNSDirector/PDMR Shareholding
5th Jan 20232:38 pmRNSDirector Declaration
12th Dec 20225:23 pmRNSDirectorate Change
12th Dec 20221:44 pmRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSCompletion of the acquisition of Air Affairs
23rd Nov 202212:16 pmRNSCompletion of the acquisition of Avantus
10th Nov 202212:13 pmRNSDirector/PDMR Shareholding
10th Nov 20227:00 amRNSInterim Results
12th Oct 20227:00 amRNSSecond Quarter Trading Update
11th Oct 20223:28 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:06 amRNSAcquisition of Air Affairs & disposal of Space NV

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.